Mereo BioPharma Group's Cash Hoard and Growth Potential

Mereo BioPharma Group (NASDAQ:MREO) has a cash runway of around 20 months, with $56m in cash and a cash burn of $33m last year. Analysts predict the company will break even before the end of the cash runway. However, the cash burn has increased by 60% over the last year, which could affect the company's cash runway. The cash burn is largely due to the company's focus on business development, which may impact its future growth.